Corbus Pharmaceuticals Holdings, Inc. (CRBP) Expands Intellectual Property Portfolio

Biotech Stocks

Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases

This patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the synthesis, manufacturing, formulation and uses of anabasum for a variety of indications including the Company’s lead indications: systemic sclerosis, dermatomyositis, cystic fibrosis and systemic lupus erythematosus. Anabasum is a synthetic oral endocannabinoid-mimetic drug candidate designed to resolve chronic inflammation and fibrosis through the activation of the CB2 receptor to stimulate production of specialized pro-resolving mediators.

Mark Tepper, Ph.D., President and Chief Scientific Officer of Corbus, stated, “The issuance of this specific patent reaffirms the unique properties of anabasum to treat systemic sclerosis, dermatomyositis, cystic fibrosis and other rare fibrotic diseases for which there are limited therapeutic options for patients. This issued patent, along with the Company’s other recently issued U.S. Patent No. 9,801,849 covering the use of anabasum for multiple inflammatory diseases, provides Corbus with broad intellectual property rights to anabasum to 2034.”

Yuval Cohen, Ph.D., CEO of Corbus, stated, “The issuance of this second key patent this year is a reflection of our success in creating and expanding a robust intellectual property portfolio around anabasum.”

About Anabasum

Anabasum is a synthetic oral endocannabinoid-mimetic drug that preferentially binds to cannabinoid receptor type 2 (CB2) expressed on activated immune cells and fibroblasts. CB2 activation triggers physiologic pathways that resolve inflammation, speed bacterial clearance and halt fibrosis. Nonclinical and human clinical studies to date have shown anabasum has favorable safety, tolerability and pharmacokinetic profiles. It has also demonstrated promising potency in nonclinical models of inflammation and fibrosis. Anabasum is designed to trigger the production of “Specialized Pro-resolving Lipid Mediators” that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of multiple inflammatory mediators. Anabasum also is designed to have a direct effect on fibroblasts to halt tissue scarring. In effect, anabasum is believed to trigger endogenous pathways to turn “off” chronic inflammation and fibrotic processes without causing immunosuppression.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has generated positive data in Phase 2 studies in diffuse cutaneous systemic sclerosis, cystic fibrosis and dermatomyositis. Additionally, the Company is evaluating anabasum in open-label extension studies in systemic sclerosis and skin-predominant dermatomyositis. The Company expects to commence a Phase 2 study in systemic lupus erythematosus, a Phase 3 study in systemic sclerosis and a Phase 2b study in cystic fibrosis in the fourth quarter of 2017.

For more information, please visit and connect with the Company on Twitter, LinkedIn, Google+ and Facebook.


Please enter your comment!
Please enter your name here